ID: MRFR/Pharma/2591-HCR | February 2021 | Region: Global | 83 pages
Tinea Versicolor is one of the common types of skin infection. It also called as pityriasis versicolor. In this condition, small and discolored patches of skin occur, mostly affecting the shoulders and trunk.
Increasing prevalence of tinea versicolor, increasing awareness of the disease, rising healthcare expenditure, advanced diagnosis and treatment options, and approval of new antifungal medicines are leading the growth of tinea versicolor treatment market.
tinea versicolor treatment market is expected to grow at the CAGR of ~7.1% during the forecast period and is estimated to reach USD 197.9 million by 2023.
Study objectives of tinea versicolor treatment market:
FIGURE 1 TINEA VERSICOLOR TREATMENT MARKET SHARE BY END USER, 2016 (%)
Sources: DermNet New Zealand Trust, National Center for Biotechnology Information (NCBI), American Academy of Dermatology, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation
Sources: DermNet New Zealand Trust, National Center for Biotechnology Information (NCBI), American Academy of Dermatology, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation.
Tinea versicolor treatment market has been segmented on the basis of diagnosis which comprise physical exam, imaging tests, and others. Imaging test is sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy, and others. Skin biopsy is sub-segmented into shave biopsy, punch biopsy, excisional biopsy, and others.
On the basis of treatments, the market has been segmented into antifungal shampoos, antifungal creams, drugs, and others. Antifungal shampoos are sub-segmented into selenium sulfide (selsun) 2.5 percent shampoo, ciclopirox (loprox, penlac) shampoo, ketoconazole (ketoconazole, nizoral, others) shampoo, and others. Antifungal creams are sub-segmented into Selenium sulfide (Selsun) 2.5 percent lotion, Ciclopirox (Loprox, Penlac) cream or gel, Ketoconazole (Ketoconazole, Nizoral, others) cream or gel, and others. Drugs are further sub-segmented into fluconazole (diflucan) tablets or oral solution, and others.
On the basis of end user, it is segmented into dermatology hospital and clinics, medical research centers, academic institutes, and others.
Regional analysis of tinea versicolor treatment market:
Considering the global scenario of the market, America is the top contributor in this market. The Americas mainly include North America and South America. Due to large amount of money invested in research, clinical trials, and new product development, US is the dominating country in this region. Europe is the second largest market for tinea versicolor treatment. Germany is dominating this market while UK is the fastest growing tinea versicolor treatment market. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly improving healthcare facilities, increasing awareness of disease, and rising healthcare expenditure. Middle East & Africa is expected to have limited growth.
Key players for Tinea Versicolor treatment market:
Some of the key players in this tinea versicolor treatment market are: Astellas Pharma US, Inc. (Japan), Bayer AG (German), Enzon Pharmaceuticals, Inc. (US), Galderma S.A. (Switzerland), Gilead (US), Novartis AG (Switzerland), Pfizer Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teva Pharmaceutical Industries Ltd. (Israel), Valeant (Canada), and others. The report for Global Tinea Versicolor Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Astellas Pharma US, Inc. (Japan), Bayer AG (German), Enzon Pharmaceuticals, Inc. (US), Galderma S.A. (Switzerland), Gilead (US), Novartis AG (Switzerland), Pfizer Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teva Pharmaceutical Industries Ltd. (Israel), Valeant (Canada), and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Tinea versicolor treatment market is set to reach USD 197.9 million by 2023.
Tinea versicolor treatment market is expected to flourish at 7.1% CAGR from 2017 to 2023.
Increasing prevalence of tinea versicolor and approval of antifungal medicines are major drivers of the global tinea versicolor treatment market.
The Americas can dominate the global tinea versicolor treatment market owing to heavy investments in research and development and ongoing clinical trials for testing of new drugs.
Gilead, Taro Pharmaceutical Industries Ltd., Enzon Pharmaceuticals, Inc., Valeant, Novartis AG, Astellas Pharma US, Inc., Pfizer Inc., Bayer AG, Galderma S., Teva Pharmaceutical Industries Ltd., and others are major players of the global tinea versicolor treatment market.
1. Report Prologue
2.2 Scope of the Study
2.2.1 Research Objective
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Upcoming trends
6. Global Tinea Versicolor Treatment Market by Diagnosis
6.1 Wood lamp (black light) examination
6.2 Microscopy using potassium hydroxide (KOH)
6.3 Fungal culture
6.4 Skin biopsy
6.4.1 Shave biopsy
6.4.2 Punch biopsy
6.4.3 Excisional biopsy
7. Global Tinea Versicolor Treatment Market by Treatment
7.1 Antifungal shampoos
7.1.1 Selenium sulfide shampoo
7.1.2 Ciclopirox shampoo
7.1.3 Ketoconazole shampoo
7.2 Antifungal creams
7.2.1 Selenium sulfide (lotion
7.2.2 Ciclopirox cream or gel
7.2.3 Ketoconazole cream or gel
7.3.1 Fluconazole tablets or oral solution
8. Global Tinea Versicolor Treatment Market by End User
8.1 Dermatology Hospital and clinics
8.2 Medical research centers
8.3 Academic institutes
9. Global Tinea Versicolor Treatment Market by Region
9.2.1 North America
220.127.116.11 The US
9.2.2 South America
9.3.1 Western Europe
18.104.22.168 Rest of Western Europe
9.3.2 Eastern Europe
9.4.4 South Korea
9.4.5 Rest of Asia
9.6 Middle East and Africa
9.6.2 Saudi Arabia
9.6.4 Rest of Middle East and Africa
10. Competitive Landscape
11. Company Profile
12.1 Key findings
12.1.1 From CEO’s viewpoint
12.1.2 Unmet needs of the market
12.2 Key companies to watch
12.3 Prediction of Tinea Versicolor Treatment Market